OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

[Guest guest]

Complete Story

http://www.newswire.ca/en/releases/archive/December2008/03/c6489.html

Highlights

The study randomized 82 patients with metastatic or locally recurringprostate cancer refractory to hormone therapy. The median survival was 27.5months for the patients in the OGX-011 arm and 16.9 months for those in the

control arm. Results currently indicate that patients in the OGX-011 arm havea death rate approximately 40% lower than patients in the control arm. Thecurrent results are based on study data with a median follow-up of

approximately 30 months for both arms. Additional survival updates are neededbefore a mature median survival for the OGX-011 arm can be reported. Based onthe current results, OncoGenex has calculated that the final median survival

for patients in the OGX-011 arm can not be lower than 22.7 months. An abstract presenting the mature results is planned to be submitted tothe American Society of Clinical Oncology (ASCO) meeting.

Anyone famliar with the studay or participating?-- Emersonwww.flhw.org